C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $582,324 | -12.1% | 313,077 | +29.9% | 0.00% | – |
| Q2 2023 | $662,858 | -28.2% | 241,039 | -18.1% | 0.00% | – |
| Q1 2023 | $923,594 | -58.7% | 294,138 | -22.4% | 0.00% | – |
| Q4 2022 | $2,237,275 | -25.9% | 379,199 | +10.1% | 0.00% | – |
| Q3 2022 | $3,019,000 | -12.1% | 344,387 | -24.4% | 0.00% | – |
| Q2 2022 | $3,434,000 | -78.5% | 455,456 | -30.7% | 0.00% | -100.0% |
| Q1 2022 | $15,954,000 | -46.1% | 657,572 | -28.4% | 0.00% | -50.0% |
| Q4 2021 | $29,575,000 | +128.2% | 918,470 | +216.6% | 0.00% | +100.0% |
| Q3 2021 | $12,961,000 | +24.0% | 290,096 | +5.0% | 0.00% | +100.0% |
| Q2 2021 | $10,451,000 | +1233.0% | 276,188 | +1203.1% | 0.00% | – |
| Q1 2021 | $784,000 | +159.6% | 21,195 | +132.7% | 0.00% | – |
| Q4 2020 | $302,000 | – | 9,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |